| 2024-10-03 | -0.79 % |
|
| 2024-10-02 | +0.42 % |
|
| 2024-10-01 | +0.41 % |
|
| 2024-09-30 | +0.54 % |
|
| 2024-09-27 | +0.32 % |
|
| 2024-09-25 | -0.01 % |
|
| 2024-09-17 | -1.19 % |
|
| 2024-09-13 | -0.62 % |
|
| 2024-09-12 | +1.07 % |
|
| 2024-09-10 | +0.5 % |
|
| 2024-09-05 | -0.72 % |
|
| 2024-09-04 | +1.01 % |
|
| 2024-08-13 | -0.03 % |
|
| 2024-08-09 | +0.85 % |
|
| 2024-08-02 | -0.88 % |
|
| 2024-07-25 | -4.5 % |
|
| 2024-07-24 | -1.06 % |
|
| 2024-07-23 | +0.41 % |
|
| 2024-07-19 | +2.66 % |
|
| 2024-07-16 | +0.15 % |
|
| 2024-07-12 | +1.04 % |
|
| 2024-07-02 | +0.18 % |
|
| 2024-07-01 | -0.78 % |
|
| 2024-06-18 | +0.16 % |
|
| 2024-06-13 | -0.58 % |
|
| 2024-06-11 | -0.35 % |
|
| 2024-06-10 | +0.4 % |
|
| 2024-06-07 | +1.3 % |
|
| 2024-06-06 | +0.3 % |
|
| 2024-06-05 | -0.04 % |
|
| 2024-06-04 | +0.56 % |
|
| 2024-06-03 | -0.09 % |
- The article announces the appointment of Mr. Jason Crawford as Chief Financial Officer of AZZ Inc., citing his prior experience and qualifications; Boston Scientific (BSX) stock went down last night by -0.09%, likely influenced by market conditions or factors specific to the company.
- The Boston Scientific (BSX) stock went down last night as one of its top executives, Wendy Carruthers, sold 6,983 shares of common stock, amounting to $526,029 in total value, through a pre-established trading plan, causing investors to pay closer attention to the company's stock performance and valuation, despite the company's optimistic earnings outlook and positive market sentiments.
|
| 2024-05-31 | +0.76 % |
|
| 2024-05-30 | +0.03 % |
|
| 2024-05-29 | -0.25 % |
|
| 2024-05-23 | -1.31 % |
|
| 2024-05-22 | -0.4 % |
- The article provides an overview of Boston Scientific's financial performance, highlighting its net income growth, margin expansion, and stock performance over the past three years. The stock of Boston Scientific (BSX) faced a -0.4% decline, possibly due to concerns over its fully valued status, despite its positive outlook and disciplined spending leading to increased net income and revenue growth in 2023.
- The article discusses a class action complaint against iRhythm Technologies, Inc., alleging that the company misrepresented its Zio AT heart monitoring device as a real-time monitor for high-risk patients, leading to inflated stock prices. Boston Scientific (BSX) stock likely went down due to its involvement in a similar DOJ investigation related to real-time monitoring products, which affected investor confidence in the sector.
- Summary: Boston Scientific (BSX) stock was down by 0.4% last night, and the decline could be attributed to the competitive market for PFA catheters leading to potential price reductions to attract more users and gain market share, especially with new competing products demonstrating superior features or performance.
Reason for Boston Scientific (BSX) stock decline: The competition in the market for PFA catheters, with major medical device companies investing in this technology, may lead to potential price reductions by companies like Boston Scientific to stay competitive and attract more users.
|
| 2024-05-21 | +0.41 % |
|
| 2024-05-20 | +0.95 % |
|
| 2024-05-16 | +0.13 % |
|
| 2024-05-15 | +1.31 % |
|
| 2024-05-13 | -1.19 % |
|
| 2024-05-03 | +1.14 % |
|
| 2024-05-02 | -0.25 % |
|
| 2024-04-26 | -0.12 % |
|
| 2024-04-25 | +0.48 % |
- The article discusses Affluent Medical's financial results and clinical updates, including the success of their medical devices KaliosTM, Epygon, and Artus, leading to a 0.48% increase in Boston Scientific (BSX) stock as they are considered potential commercial partners such as Medtronic, Abbott, and Edwards Life Science.
- The article is about Boston Scientific Corporation's (BSX) Q1 2024 earnings call, where they reported exceeding expectations with operational sales growth, guided to strong outlook for 2024, and highlighted growth across different business units and regions. Boston Scientific stock likely went up due to the company's strong financial performance, exceeding guidance, and positive outlook for the future.
- The article discusses how AstraZeneca's (AZN) stock surged after reporting strong sales and beating projections with its cancer treatments, which resulted in a 5.4% increase in stock value, potentially positively affecting related industries like healthcare and pharmaceuticals, possibly leading to a positive sentiment spillover and driving Boston Scientific (BSX) stock up as well.
|
| 2024-04-24 | +5.68 % |
|
| 2024-04-23 | +1.43 % |
- The article discusses Edwards Lifesciences, a medical device company focusing on cardiovascular products, highlighting its divisions and financial performance. It mentions that despite competitive pressures in the aortic valve business, the company has shown strong growth in sales and profitability, with a net cash position and good profitability ratios. The stock of Boston Scientific (BSX) rose by 1.43% last night, likely influenced by positive market sentiment and potential growth opportunities in the medical device industry.
- Summary: Cetera Trust Company N.A acquired a new position in Boston Scientific Co., leading to a 1.43% increase in the stock price, attributed to various other hedge funds and institutional investors adding to their stakes in BSX, coupled with positive analyst ratings and the company's strong financial performance.
Reason for Boston Scientific (BSX) stock increase: The rise in Boston Scientific's stock can be attributed to institutional investors like Cetera Trust Company N.A and other hedge funds increasing or maintaining their positions in the company, positive analyst ratings, and the company's solid financial performance, as highlighted by its recent earnings report beating consensus estimates.
|
| 2024-04-22 | +1.02 % |
- The article provides information about Boston Scientific (BSX) stock, which was up 1.02% last night, and upcoming earnings report, expecting earnings of $0.51 per share with a positive outlook based on recent results and analyst expectations, with insider selling noted and significant institutional investor interest. BSX stock has seen positive analyst ratings and price target upgrades, likely contributing to its recent increase.
- The article discusses how Boston Scientific's stock was up by 1.02% last night, and this increase may be attributed to growth in positions by notable fund managers like Signaturefd LLC, FMR LLC, Vanguard Group Inc., Wellington Management Group LLP, Geode Capital Management LLC, and DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main. The stock's rise could also be influenced by positive analyst ratings and earnings results exceeding expectations, showing promising financial performance.
- Boston Scientific's stock (BSX) went up 1.02% last night following Evercore ISI's positive outlook on Stryker Corporation (SYK), which maintained an Outperform rating and a $370.00 price target for its stock; the rise in BSX stock was due to Stryker's performance trailing behind Boston Scientific by about 900 basis points since the unveiling of Intuitive Surgical's (ISRG) da Vinci 5 (dV5) surgical system in mid-March.
|
| 2024-04-19 | -0.13 % |
|
| 2024-04-18 | -0.79 % |
|
| 2024-04-17 | -0.23 % |
|
| 2024-04-16 | +1.01 % |
|
| 2024-04-11 | +0.28 % |
|
| 2024-04-10 | -0.01 % |
|
| 2024-04-09 | -0.04 % |
|
| 2024-04-08 | +0.19 % |
|
